Understanding patient preferences for the treatment of lupus nephritis with adaptive conjoint analysis

Medical Care

Volumn 39, Issue 11, 2001, Pages 1203-1215

  Fraenkel, Liana ^a,b,c   Bodardus, Sidney ^a   Wittink, Dick R ^a  

^a YALE UNIVERSITY   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Conjoint analysis; Lupus nephritis; Patient preferences

Indexed keywords

ANTIRHEUMATIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE;

ADULT; ARTICLE; CLINICAL TRIAL; DECISION MAKING; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT PARTICIPATION; PATIENT SATISFACTION; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICS; SURVIVAL; THEORETICAL MODEL; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; CONNECTICUT; CYCLOPHOSPHAMIDE; DECISION MAKING; FEMALE; HUMANS; LEAST-SQUARES ANALYSIS; LUPUS NEPHRITIS; MIDDLE AGED; MODELS, THEORETICAL; PATIENT PARTICIPATION; PATIENT SATISFACTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035515414     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-200111000-00007     Document Type: Article

References (56)

1. Speedling EJ, Rose DN. Building an effective doctor-patient relationship: From patient satisfaction to patient participation. Soc Science Med 1985;21:115-120.
2. Kaufmann CL. Informed consent and patient decision making: Two decades of research. Soc Science Med 1983;17:1657-1664.
3. Daltroy LH. Doctor-patient communication in rheumatological disorders. Baillieres Clin Rheumatol 1993;7:221-239.
4. Mazur DJ. Informed consent: court viewpoints and medical decision making. Med Decis Making 1986;6:224-230.
5. Llewellyn-Thomas HA. Patients' health-care decision making: a framework for descriptive and experimental investigations. Med Decis Making 1995;15:101-106.
6. Llewellyn-Thomas HA, Naylor CD, Cohen MM, et al. Studying patients' preferences in health care decision making. Can Med Assoc J 1992;147:859-864.
7. Llewellyn-Thomas HA, Sutherland HJ, Ciampi A, et al. The assessment of values in laryngeal cancer: reliability of measurement methods. J Chron Dis 1984;37:283-291.
8. Llewellyn-Thomas HA, Thiel EC, Sem FW, et al. Presenting clinical trial information: a comparison of methods. Patient Educ Counsel 1995;25:97-107.
9. Llewellyn-Thomas HA. Health state descriptions. Purposes, issues, a proposal. Med Care 1996;34(Suppl):DS109-118.
10. Green PE, Srinivasan V. Conjoint analysis in marketing: new developments with implications for research and practice. J Marketing 1990;54:3-17.
11. Johnson RM. Adaptive Conjoint Analysis. Sawtooth Software Conference Proceedings. Ketchum, ID: 1987:253-265.
12. Wittink DR, Cattin P. Commercial use of conjoint analysis: an update. J Marketing 1998;53:91-96.
13. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000;320:1530-1533.
14. Vick S, Scott A. What makes a perfect agent? A pilot study of patients' preferences in the doctor patient relationship J Health Econ 1998;17:587-606.
15. Scott A, Vick S. Patients, doctors, and contracts: an application of principal-agent theory to the doctor-patient relationship. Scot J Political Econ 1999;46:111-134.
16. Singh J, Cuttler L, Mincheol S, et al. Medical decision making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. Med Care 1998;36:AS31-AS45.
17. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ 1997;6:261-273.
18. Wright P. Consumer choice strategies: simplifying vs. optimizing. J Marketing Res 1975;12:60-67.
19. Srinivasan V, Park CS. Surprising robustness of the self-explicated approach to customer preference structure measurement. J Marketing Res 1997;34:286-291.
20. Wittink DR, Reibstein DJ, Boulding W, et al. Conjoint Reliability Measures. Market Science Fall 1989:371-374.
21. Balow JE, Austin HA, Tsokos GC, et al. Lupus Nephritis. Ann Intern Med 1987;106:79-94.
22. Austin HA, Boumpas DT. Treatment of lupus nephritis. Semin Nephrol 1996;16:527-535.
23. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-1533.
24. Klippel JH, Austin III HA, Balow JE, et al. Studies of immunosuppressive drugs in the treatment of lupus nephritis. Rheum Dis Clin North Am 1987;13:47-56.
25. Boumpas DT, Austin HAD, Vaughan EM, et al. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993;119:366-369.
26. Boumpas DT, Austin HAD, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-745.
27. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only [see comments]. Arthritis Rheum 1991;34:945-950.
28. Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990;33:121-130.
29. Arthritis Today's Drug Guide. Arthritis Foundation; 1999.
30. Gourely MF. Immune suppressive medications: their benefits and side effects. Lupus News 1998:12-13.
31. Katz RS. Imuran, cytoxan and related drugs: Lupus Foundation of America; 1995.
32. Mazur DJ, Hickam DH. Patients' interpretations of probability terms [see comments]. J Gen Intern Med 1991;6:237-240.
33. Goulet JR, Mackenzie T, Levinton C, et al. The longterm prognosis of lupus nephritis: the impact of disease activity. J Rheumatol 1993;20:59-65.
34. Martin F, Lauwerys B, Lefebvre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997;6:254-257.
35. Sawtooth Software Inc. Creating an ACA questionnaire. In: Metegrano M, ed. ACA system: version 4.0 Sequim: Sawtooth Software; 1996.
36. Ende J, Kazis L, Ash A, et al. Measuring patients' desire for autonomy: decision making and information seeking preferences among medical patients. J Gen Intern Med 1989;4:23-30.
37. Fraenkel L, Bogardus S, Concato J, et al. Preference for disclosure of information among patients with rheumatoid arthritis. Arthritis Care Res 2001; 45:136-139.
38. Degner LF, Sloan JA. Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol 1992;45:941-950.
39. Brundage MD, Davidson JR, Mackillop WJ, et al. Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer. Med Decis Making 1998:256-267.
40. Fraenkel L, Bogardus S, Concato J, et al. Does decreasing the likelihood of toxicity make rheumatoid arthritis patients more likely to use DMARDs? Arthritis Rheum 2000;43(Suppl):S140.
41. Fraenkel L, Bogardus S, Concato J, et al. Unwillingness of rheumatoid arthritis patients to accept the risk for adverse effects. Arthritis Rheum 2000;43(Suppl):S140.
42. Ho M, LaB, Pullar T. The risk for treatment: a study of rheumatoid arthritis patients' attitudes. Br J Rheumatol 1998;37:459-460.
43. Bogardus STJ, Holmboe E, Jekel JF. Perils, pitfalls, and possibilities in talking about medical risk. JAMA 1999;281:1037-1041.
44. Mazur DJ. What should patients be told prior to a medical procedure? Ethical and legal perspectives on medical informed consent Am J Med 1986;81:1051-1054.
45. Ward MM. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000;160:3136-3140.
46. Coates A, Abraham S, Kaye SB, et al. On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-208.
47. Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an 'acceptable' risk in the treatment of rheumatic disease? [see comments]. Br J Rheumatol 1990;29:215-218.
48. Slovic P, Fischoff B, Lichtenstein S. Rating the risks. Environment 1979;14-20:36-39.
49. O'Brien BJ, Elswood J, Calin A. Willingness to accept risk in the treatment of rheumatic disease. J Epidemiol Comm Health 1990;44:249-252.
50. Feldman-Stewart D, Brundage MD, Hayter C, et al. What questions do patients with curable prostate cancer want answered? Med Decis Making 2000;20:7-19.
51. Mazur DJ, Hickam DH. The effect of physician's explanations on patients' treatment preferences: Five-year survival data. Med Decis Making 1994;14:255-258.
52. Greenfield S, Kaplan S, Ware JE, Jr. Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 1985;102:520-528.
53. Vertinsky IB, Thompson WA, Uyeno D. Measuring consumer desire for participation in clinical decision making. Health Serv Res 1974;9:121-134.
54. Benbassat J, Pilpel D, Tidhar M. Patients' preferences for participation in clinical decision making: a review of published surveys. Behavioral Med 1998;24:81-88.
55. Guadagnoli E, Ward P. Patient participation in decision-making. Soc Sci Med 1998;47:329-339.
56. Coulter A. Paternalism or partnership? Patients have grown up- and there's no going back BMJ 1999;319:719-720.